Genfit S.A. (GNFT)

Compare

3.3936

-0.0064

(-0.19%)

As of 12:30:37 PM EDT. Market Open.

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders

GENFIT completes a royalty financing of up to €185 million with HCRx after unanimous OCEANE bondholder approval, triggering a €130 million upfront payment with potential for an additional €55 million upon achieving near-term milestonesNon-dilutive financing extends cash runway beyond 2027 and supports GENFIT’s R&D effortsFinancing strengthens GENFIT's ACLF pipeline development and commitment to transformative therapiesGENFIT to use €61.66 million to repurchase 1,882,891 2025 OCEANEs after exerci

GlobeNewswire 13 days ago

GNFT
-0.19%
GNFTF
Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

All resolutions approved by bondholders Closing of Royalty Financing and receipt of first €130 million instalment expected shortlyUpon closing of the Royalty Financing, GENFIT will implement the Repurchase of the 2025 OCEANEs and pay the Consent Fee Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver disease

GlobeNewswire 23 days ago

GNFT
-0.19%
GNFTF
GENFIT Announces Revenues and Cash Position as of December 31, 2024

Cash and cash equivalents totaled €81.8 million as of December 31, 2024Revenues amounted to €67.0 million as of December 31, 2024 including the €48.7 million milestone upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 27, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with ra

GlobeNewswire last month

GNFT
-0.19%
GNFTF
GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting

Put Option Agreements signed to date with 2025 OCEANEs holders representing 95.3% of the outstanding 2025 OCEANEs2025 OCEANEs holders' general meeting convened for March 10, 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 21, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that it has signed Put Option Agreements with 202

GlobeNewswire last month

GNFT
-0.19%
GNFTF
GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders

In conjunction with the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, GENFIT will request the consent of the holders of 2025 OCEANEs and proposes: to repurchase the 2025 OCEANEs at EUR 32.00 per bond from interested bondholders, or alternativelyto pay a consent fee of EUR 0.60 per bond still outstanding after the upcoming bondholder meeting and cancellation of the repurchased 2025 OCEANEs Both proposals are subject to approval of the royalty financing by th

GlobeNewswire last month

GNFT
-0.19%
GNFTF
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

2 new ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b also expected by year-end 2025 for GNS561/trametinib in KRAS-mutated cholangiocarcinoma, to support dose selection for Phase 2 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 6, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated

GlobeNewswire last month

GNFT
-0.19%
GNFTF
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital: €130 million upfront, with eligibility to receive up to €55 million in two additional instalments based on near-term milestonesClosing subject to approval by the 2025 OCEANE bondholders at upcoming bondholders meetingFinancing would extend cash runway beyond the end of 2027, assuming drawdown of all instalmentsProceeds to further strengthen the development of the ACLF pipeline In

GlobeNewswire 2 months ago

GNFT
-0.19%
GNFTF
GENFIT Announces 2025 Financial Calendar

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2025. 2025 Financial Calendar February 27, 2025 Publication of revenue and cash position at December 31, 2024 April 24, 2025 Publication of Full Year 2024 financial statements The

GlobeNewswire 2 months ago

GNFT
-0.19%
GNFTF
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 13, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity accoun

GlobeNewswire 2 months ago

GNFT
-0.19%
GNFTF
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with expectations; encouraging feedback from healthcare providers and payers in the U.S.UK NICE reimbursement approved and first reimbursed sales in Germany in October 2024Next €26.5M milestone payment by Ipsen pending a third pricing and reimbursement approval in Europe Scientific progress in ACLF to be featured at The Liver Meeting® 2024, with 4 posters

GlobeNewswire 4 months ago

GNFT
-0.19%
GNFTF
GENFIT Reports Third Quarter 2024 Financial Information

Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30, 2024, including the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland); November 7, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopha

GlobeNewswire 4 months ago

GNFT
-0.19%
GNFTF
High Growth Tech Stocks in France for October 2024

As the French CAC 40 Index experiences modest gains amid broader European optimism for potential interest rate cuts, the high-growth tech sector in France remains a focal point for investors seeking opportunities in an evolving market landscape. Identifying promising stocks often involves looking at companies with innovative technologies and strong growth potential, especially as economic conditions and policy shifts create a dynamic backdrop.

Simply Wall St. 5 months ago

VIVHY

VVVNF

GNFT
-0.19%
High Growth Tech Stocks in France to Watch This October 2024

As global markets experience fluctuations, with the pan-European STOXX Europe 600 Index seeing a modest rise amid potential ECB rate cuts and economic stimuli from China, France's CAC 40 Index also recorded a slight increase of 0.48%. In this dynamic environment, identifying high-growth tech stocks in France requires focusing on companies that demonstrate robust innovation capabilities and adaptability to shifting economic landscapes.

Simply Wall St. 5 months ago

OVHFF

OVHGY

BOIVF
Believe Leads These 3 High Growth Tech Stocks In France

As the pan-European STOXX Europe 600 Index shows signs of optimism with a modest rise amid hopes for quicker interest rate cuts by the European Central Bank, France's CAC 40 Index has also experienced a slight increase, reflecting a cautiously positive sentiment in the region. In this environment, identifying high-growth tech stocks requires attention to companies that demonstrate resilience and adaptability to evolving economic conditions and regulatory landscapes.

Simply Wall St. 5 months ago

BOIVF

BLV.PA

GNFT
-0.19%
High Growth Tech Stocks In France October 2024

As the French market navigates through a period of heightened caution due to escalating Middle East tensions and broader European economic concerns, the CAC 40 Index has experienced a notable decline. In this environment, identifying high-growth tech stocks in France requires an understanding of companies that can demonstrate resilience and adaptability amidst geopolitical uncertainties and shifting economic landscapes.

Simply Wall St. 5 months ago

INRLF

VALN

GNFT
-0.19%
High Growth Tech Stocks in France to Watch October 2024

As the pan-European STOXX Europe 600 Index recently ended 1.80% lower due to escalating Middle East tensions, France's CAC 40 Index also saw a decline of 3.21%, reflecting cautious investor sentiment amid geopolitical uncertainties and anticipation of an ECB rate cut due to slowing growth and inflation. In this environment, identifying high-growth tech stocks in France requires focusing on companies with strong innovation potential and resilience against macroeconomic pressures, as these...

Simply Wall St. 5 months ago

LCTSF

BLV.PA

GNFT
-0.19%
Exclusive Networks And 2 High Growth Tech Stocks In France

As the French market grapples with broader European economic challenges, including a decline in major indices like the CAC 40 due to escalating Middle East tensions and cautious investor sentiment, high-growth tech companies remain a focal point for potential resilience and opportunity. In this environment, identifying strong tech stocks often hinges on their ability to innovate and adapt swiftly to changing market dynamics while maintaining robust growth trajectories.

Simply Wall St. 5 months ago

INRLF

VALN

EXNWF
Esker And Two High Growth Tech Stocks In France

With the recent Fed rate cuts and a cautious but optimistic outlook for monetary policy in Europe, the market sentiment has been buoyant, particularly benefiting smaller-cap stocks. In this context, high-growth tech stocks in France present intriguing opportunities for investors seeking dynamic growth potential. When evaluating such stocks, it's crucial to consider their innovation capabilities and adaptability to evolving market conditions.

Simply Wall St. 6 months ago

ESKEF

GNFT
-0.19%
GNFTF
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the European Commission has conditionally approved Iqirvo®1 (elafibranor) 80mg tablets for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an ina

GlobeNewswire 6 months ago

GNFT
-0.19%
GNFTF
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC)€59.0 million in revenues, including the €48.7 million milestone invoiced in June 2024 Positive opinion from the European Medicines Agency Committee in July 2024, with final decision on marketing authorization for Iqirvo anticipat

GlobeNewswire 6 months ago

GNFT
-0.19%
GNFTF

Performance Overview

Return	GNFT	CAC 40 (^FCHI)
YTD	-8.03%	+2.96%
1-Year	-4.94%	-6.80%
3-Year	-12.98%	+13.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Genfit S.A. (GNFT)

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

GENFIT Announces Revenues and Cash Position as of December 31, 2024

GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting

GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

GENFIT Announces 2025 Financial Calendar

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

GENFIT Reports Third Quarter 2024 Financial Information

High Growth Tech Stocks in France for October 2024

High Growth Tech Stocks in France to Watch This October 2024

Believe Leads These 3 High Growth Tech Stocks In France

High Growth Tech Stocks In France October 2024

High Growth Tech Stocks in France to Watch October 2024

Exclusive Networks And 2 High Growth Tech Stocks In France

Esker And Two High Growth Tech Stocks In France

GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update

Performance Overview